Form 4: Edgewise Therapeutics Director Receives Stock Option Grant

Director Laura Brege was granted 16,377 stock options in Edgewise Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Laura Brege received a grant of 16,377 stock options on June 5, 2026.
• The options have an exercise price of $35.59 per share.
• The options are scheduled to vest on June 5, 2027, or the day before the 2027 annual meeting, whichever occurs first.
• The options expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $35.59 exercise price.

Future Outlook

The options vest in one year, signaling a commitment to the company's performance through at least the 2027 annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is standard for annual director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 5, 2027.

Key Dates

Keywords

EWTX, Edgewise Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation